investing.comNov 9$CRMD

CorMedix stock gains as Heron deal adds four products

CorMedix (CRMD) shares rose 4.5% premarket after announcing a $222.6M deal to acquire Heron Therapeutics' (HRTX) assets, including four commercial products. CorMedix will pay $145M cash and issue 14.6M shares. The deal is expected to close in Q1 2027 and be immediately accretive to earnings, with pro forma 2026 revenue estimated at $465M-$490M.

Original reporting

investing.com

Published Nov 9, 2026, 1:29 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 1:43 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefMergers & acquisitions

Primary signal

$CRMD

Bullish

high confidence

Mentioned

$CRMD · $HRTX

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$CRMDBullishHigh

Why it matters

The acquisition is expected to be immediately accretive, expanding CRMD's product suite and revenue base while providing a premium to HRTX shareholders.

Market read

First‑report M&A deal with $222M transaction size and double‑digit stock moves, offering clear trading opportunities.

What to watch

Potential regulatory approvals for the acquired products and earn‑out performance risk.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

CorMedix (CRMD) and Heron Therapeutics (HRTX) are small‑cap biotech firms focused on acute‑care and oncology supportive care.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CRMDBullishHigh confidence

Context

CorMedix announced acquisition of Heron Therapeutics assets for $222.6M, driving a 4.5% pre‑market rise.

Expected impact

likely upward pressure as market prices in earnings accretion and synergies

Evidence & confidence

Deal adds four commercial‑stage products and cost synergies; investors responded with a pre‑market rally.

$HRTXBullishHigh confidence

Context

Heron Therapeutics stock surged 45% after the acquisition announcement with CRMD.

Expected impact

likely continued upward pressure as the premium is priced in

Evidence & confidence

The premium and earn‑out terms provide immediate value to shareholders, reflected in the large price move.

Market effects

Sector

Adds four oncology/anti‑nausea products to CRMD's portfolio, strengthening its position in the hospital‑care market.

Regional

US hospital‑care and specialty pharma sectors may see modest re‑rating.

Global

Limited to US‑listed biotech and pharma investors.

Counterpoint

What could challenge this read

Deal valuation may be high if product uptake falls short; integration risk could weigh on CRMD.

Key entities

Company
CorMedix Inc
Acquirer, NASDAQ:CRMD
Company
Heron Therapeutics Inc
Target, NASDAQ:HRTX

Read at source ← All news

$CRMDHighAI 8/10

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix (CRMD) will acquire assets from Heron, adding four products and aiming for $60M in savings. Heron may receive up to $55M in additional payments tied to ZYNRELEF's 2028 sales. CorMedix will fund the deal with $70M in cash and a $150M loan. Heron's convertible debt holders will convert debt into CorMedix stock. CorMedix plans to relaunch SUSTOL and focus on APONVIE, with a potential FDA approval for an undisclosed injectable product in 2027.

finance.yahoo.comNov 10

$CRMDHighAI 8/10

CorMedix stock maintains outperform rating on Heron acquisition

Citizens reiterated an Outperform rating and $19.00 price target on CorMedix (CRMD). The company agreed to acquire Heron Therapeutics' assets for $225M, expecting to close in Q1 2027. CRMD reported Q2 2026 earnings of $0.29/share on $101.9M revenue, beating estimates. Analysts highlight strategic fit, revenue diversification, and strong financials.

investing.comNov 10

$CRMDMed

Key facts: CorMedix to Acquire Heron’s Four Commercial Assets for $145M, Shares and Earn-Outs

CorMedix (CRMD) will acquire four commercial products from Heron Therapeutics for $145M in cash, 14.6M shares, and up to $55M in earn-outs. The deal, expected to close in Q1 2027, includes therapies for post-surgery pain, nausea, and chemotherapy-related nausea. CorMedix plans to sell these products through its existing network.

tradingview.comNov 10

$HRTXHigh

Heron Therapeutics Reports Q3 Revenue Of $35.3 Mln; Agrees To Sell Assets To CorMedix

Heron Therapeutics (HRTX) reported Q3 2026 revenue of $35.3M, down from $38.2M YoY. Acute Care revenue grew 22.5% YoY, while Oncology Supportive Care declined. Heron agreed to sell all assets to CorMedix (CRMD) for $145M cash, 14.58M CRMD shares, and up to $55M in earn-outs. The deal is expected to close in Q1 2027. HRTX and CRMD shares are up 30.00% and 2.07% respectively.

rttnews.comNov 9

$CRMDHighAI 9/10

CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up

CorMedix (CRMD) will acquire Heron's (HRTX) assets for $222.6M upfront, including cash and stock, with potential earn-outs. The deal adds four commercial-stage products to CorMedix's portfolio, expected to close in 2027. CorMedix anticipates earnings accretion and cost synergies, while Heron will remain public and evaluate future opportunities. Both stocks rose on the news.